arrow
A

Anders Waage

Norwegian University of Science and Technology
H指数:67
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TCR T cells targeting IgA- and IgG-expressing multiple myeloma

靶向表达IgA和IgG的多发性骨髓瘤的TCR T细胞

Blood
IF23.1
2026-03-040
OA
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial

随机临床试验中的适应性设计:HOVON87/NMSG18多发性骨髓瘤试验的再分析

2025-10-300
OAAI
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

基于EMN–HARMONY联盟平台的机器学习风险分层策略用于多发性骨髓瘤:见解

2025-10-090
OAAI
Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

鉴定具有增强活性的肝样促红细胞生成素作为遗传性和获得性红细胞增多症的新病因

BLOOD
IF23.1
2024-11-250
PRE
Deciphering the genetics and mechanisms of predisposition to multiple myeloma

解读多发性骨髓瘤易感性的遗传学和机制

2024-08-052
OAAI
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
2023-09-011
OAAI
Functional dissection of inherited non-coding variation influencing multiple myeloma risk (vol 13, 151, 2022)
2022-12-130
OAAI
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence

多发性骨髓瘤治疗压力后的克隆进化: 异源基因组畸变和转录组学收敛

LEUKEMIA
IF13.4
2022-05-2836
OAAI
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

完全缓解的多发性骨髓瘤患者的纵向最小残留疾病评估-EMN02/HO95 MM试验中NMSG flow-MRD子研究的结果

2022-02-052
OAAI
Functional dissection of inherited non-coding variation influencing multiple myeloma risk
2022-01-1016
OAAI
Germline variants at SOHLH2 influence multiple myeloma risk
2021-04-1911
OAAI